title: Endogenous tumor-reactive CD8+T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth.
abstract: Immunotherapies aimed at enhancing natural or endogenous antitumor T-cell immunity in patients affected by advanced malignancies are currently being implemented in the clinic with promising results. In order to optimize therapeutic protocols and monitor the effectiveness of such therapies, reliable biomarkers are needed. We used CD11a, an integrin that is upregulated on the surface of effector and memory CD8+T cells, and PD-1, an immunoregulatory receptor expressed by activated T cells, as biomarkers to identify, quantify and monitor endogenous tumor-reactive cytotoxic T lymphocytes (CTLs) in two mouse tumor models and in the peripheral blood of 12 patients affected by Stage IV melanoma. High expression levels of CD11a and PD-1 were detected among CD8+T cells residing within primary and metastatic murine tumor sites, as well as in spontaneous murine breast cancer tissues. In the peripheral blood of melanoma patients, tumor antigen-specific CD8+T cells were associated with a population of CD11ahighCD8+T cells that co-expressed high levels of PD-1. Healthy donors exhibited a comparatively much lower frequency of such PD-1+CD11ahighCD8+T cells. Phenotypic analyses demonstrated that CD11ahighCD8+T cells are proliferating (Ki67+) and activated (CD62L-CD69+). Increased CD11ahighCD8+T cells and delayed tumor growth were observed in PD-1 deficient mice, suggesting that the antitumor effector functions of CD8+T cells is compromised by an elevated expression of PD-1. The CD11ahighCD8+T-cell population expresses high levels of PD-1 and presumably constitutes the cellular target of PD-1 blockade therapy. The expression level of CD11a and PD-1 by CD8+T cells may therefore represent a novel biomarker to identify and monitor endogenous tumor-reactive CTLs. This may not only provide an immunological readout for evaluating the efficacy of immunotherapy but also contribute to the selection of cancer patients who are likely to benefit from anti-PD-1 therapy.
authors.affiliation: Department of Urology; College of Medicine; Mayo Clinic; Rochester, MN USA.
authors.forename: Xin
authors.initials: X
authors.lastname: Liu
authors.forename: Rachel M
authors.initials: RM
authors.lastname: Gibbons
authors.forename: Susan M
authors.initials: SM
authors.lastname: Harrington
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Krco
authors.forename: Svetomir N
authors.initials: SN
authors.lastname: Markovic
authors.forename: Eugene D
authors.initials: ED
authors.lastname: Kwon
authors.forename: Haidong
authors.initials: H
authors.lastname: Dong
keywords: CD11a; PD-1; T-cell marker; antitumor immunity
references.citation: J Mol Med (Berl). 2003 May;81(5):281-7
references.pmid: 12721664
references.citation: Nature. 2006 Feb 9;439(7077):682-7
references.pmid: 16382236
references.citation: Clin Cancer Res. 2013 Jan 15;19(2):462-8
references.pmid: 23169436
references.citation: Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
references.pmid: 12218188
references.citation: J Exp Med. 2000 Apr 3;191(7):1241-6
references.pmid: 10748241
references.citation: Blood. 2009 Aug 20;114(8):1537-44
references.pmid: 19423728
references.citation: J Immunol Methods. 2003 Oct 1;281(1-2):65-78
references.pmid: 14580882
references.citation: J Immunol. 2011 Jul 1;187(1):7-9
references.pmid: 21690331
references.citation: Annu Rev Immunol. 2011;29:235-71
references.pmid: 21219185
references.citation: Clin Exp Immunol. 2003 Nov;134(2):246-52
references.pmid: 14616784
references.citation: Oncoimmunology. 2012 Oct 1;1(7):1061-1073
references.pmid: 23170254
references.citation: Nat Immunol. 2003 Nov;4(11):1083-92
references.pmid: 14528303
references.citation: Nat Immunol. 2011 Jun 20;12(7):597-606
references.pmid: 21685955
references.citation: J Immunol. 2002 Apr 1;168(7):3484-92
references.pmid: 11907109
references.citation: N Engl J Med. 2012 Jun 28;366(26):2455-65
references.pmid: 22658128
references.citation: Proc Natl Acad Sci U S A. 2005 May 3;102(18):6437-42
references.pmid: 15851656
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1757-61
references.pmid: 17363529
references.citation: Cancer Res. 2004 Feb 1;64(3):1140-5
references.pmid: 14871849
references.citation: J Exp Med. 2011 Sep 26;208(10):1989-2003
references.pmid: 21930769
references.citation: J Cell Sci. 2009 Jan 15;122(Pt 2):215-25
references.pmid: 19118214
references.citation: J Immunol. 2004 Aug 15;173(4):2222-6
references.pmid: 15294931
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: J Exp Med. 1998 Aug 3;188(3):589-96
references.pmid: 9687535
references.citation: J Exp Med. 2011 Sep 26;208(10):2005-16
references.pmid: 21930765
references.citation: Cancer Res. 2007 Feb 1;67(3):1326-34
references.pmid: 17283170
references.citation: Nat Rev Immunol. 2003 Jan;3(1):51-62
references.pmid: 12511875
references.citation: J Exp Med. 1996 Apr 1;183(4):1415-26
references.pmid: 8666900
references.citation: Nat Immunol. 2012 Dec;13(12):1129-32
references.pmid: 23160205
references.citation: J Clin Invest. 2011 Jun;121(6):2350-60
references.pmid: 21555851
references.citation: Blood. 2009 Aug 20;114(8):1528-36
references.pmid: 19420358
references.citation: Blood. 2009 Aug 20;114(8):1545-52
references.pmid: 19417208
references.citation: J Immunol. 2002 Nov 15;169(10):5522-30
references.pmid: 12421928
references.citation: Cancer Res. 2007 Dec 1;67(23):11195-201
references.pmid: 18056444
references.citation: Eur J Immunol. 1993 Aug;23(8):1859-65
references.pmid: 8344347
references.citation: Nat Med. 2002 Aug;8(8):793-800
references.pmid: 12091876
references.citation: J Immunol. 2005 Dec 15;175(12):7855-66
references.pmid: 16339521
references.citation: Cancer Res. 2005 Apr 1;65(7):2938-46
references.pmid: 15805297
references.citation: J Cell Physiol. 2000 Mar;182(3):311-22
references.pmid: 10653597
references.citation: Nature. 1989 Oct 19;341(6243):619-24
references.pmid: 2477710
references.citation: Immunity. 2004 Mar;20(3):327-36
references.pmid: 15030776
references.citation: J Exp Med. 2010 Aug 2;207(8):1791-804
references.pmid: 20660615
references.citation: Nature. 1985 Jan 24-30;313(6000):318-20
references.pmid: 3918270
references.citation: J Immunol. 2004 Sep 15;173(6):3653-9
references.pmid: 15356110
references.citation: J Immunol. 2011 May 15;186(10):5784-90
references.pmid: 21482735
references.citation: PLoS Pathog. 2010 Jul 15;6(7):e1000998
references.pmid: 20657824
references.citation: Transplantation. 2001 Sep 15;72(5):764-9
references.pmid: 11571432
references.citation: J Immunol. 2009 Dec 15;183(12):7672-81
references.pmid: 19933864
references.citation: FEBS Lett. 2004 Sep 10;574(1-3):37-41
references.pmid: 15358536
references.citation: Blood. 2010 Aug 26;116(8):1272-9
references.pmid: 20472831